BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36875116)

  • 1. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.
    Li S; Wu J; Wu J; Fu Y; Zeng Z; Li Y; Li H; Liao W; Yan M
    Front Immunol; 2023; 14():1109771. PubMed ID: 36875116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy.
    Sheng R; Zeng M; Jin K; Zhang Y; Wu D; Sun H
    Acad Radiol; 2022 Jun; 29(6):819-829. PubMed ID: 34649778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads.
    Cheng S; Yu X; Liu S; Jin Z; Xue H; Wang Z; Xie P
    Cancer Manag Res; 2021; 13():9367-9377. PubMed ID: 34992462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy.
    Liu B; Gao S; Guo J; Kou F; Liu S; Zhang X; Wang X; Cao G; Chen H; Liu P; Xu H; Gao Q; Yang R; Zhu X
    Transl Oncol; 2023 Aug; 34():101705. PubMed ID: 37257332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
    Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
    J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts.
    Yuan G; Xie F; Song Y; Li Q; Li R; Hu X; Zang M; Cheng X; Lu G; Huang J; Fan W; Rong X; Sun J; Chen J
    Front Immunol; 2022; 13():868809. PubMed ID: 35757765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.
    Deng PZ; Zhao BG; Huang XH; Xu TF; Chen ZJ; Wei QF; Liu XY; Guo YQ; Yuan SG; Liao WJ
    World J Gastroenterol; 2022 Aug; 28(31):4376-4389. PubMed ID: 36159012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a nomogram for survival prediction in hepatocellular carcinoma after partial hepatectomy.
    Lu Y; Ren S; Jiang J
    BMC Surg; 2023 Jan; 23(1):27. PubMed ID: 36717904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study.
    Zhang XP; Chen ZH; Zhou TF; Li LQ; Chen MS; Wen TF; Shi J; Guo WX; Wu MC; Lau WY; Cheng SQ;
    Eur J Surg Oncol; 2019 Sep; 45(9):1644-1651. PubMed ID: 30982657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort.
    Zhan G; Peng H; Zhou L; Jin L; Xie X; He Y; Wang X; Du Z; Cao P
    Front Endocrinol (Lausanne); 2023; 14():1070396. PubMed ID: 36798659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.
    Ouyang J; Yang Y; Zhou Y; Ye F; Wang Z; Li Q; Xu Y; Li L; Zhao X; Zhang W; Zhou A; Huang Z; Wang Y; Cai J; Zhao H; Zhou J
    Hepatol Int; 2023 Dec; 17(6):1519-1531. PubMed ID: 37707759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
    Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
    Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
    Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
    Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
    Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.
    Yuan G; Song Y; Li Q; Hu X; Zang M; Dai W; Cheng X; Huang W; Yu W; Chen M; Guo Y; Zhang Q; Chen J
    Front Immunol; 2020; 11():613946. PubMed ID: 33488622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection.
    Liu F; Guo X; Dong W; Zhang W; Wei S; Zhang S; Zhu X; Zhou W; Zhang J; Liu H
    Int J Biol Sci; 2020; 16(16):3210-3220. PubMed ID: 33162826
    [No Abstract]   [Full Text] [Related]  

  • 19. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy.
    Liu Q; Li J; Liu F; Yang W; Ding J; Chen W; Wei Y; Li B; Zheng L
    Cancer Imaging; 2020 Nov; 20(1):82. PubMed ID: 33198809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomogram predicting survival of hepatocellular carcinoma with portal vein tumour thrombus after curative resection.
    Hu Y; You S; Yang Z; Cheng S
    ANZ J Surg; 2019 Jan; 89(1-2):E20-E25. PubMed ID: 30117625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.